Latest Ratios: P/E Ratio 17.9x · EV/EBITDA 4.3x · ROE 22.6%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.1B | $162M | $119M | $1.2B | — | — | — | — | — | — |
| Enterprise Value | $1.3B | $1.3B | $458M | $373M | $1.4B | — | — | — | — | — | — |
| P/E Ratio → | 17.93 | 15.71 | 3.26 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.28 | 1.27 | 0.34 | 0.48 | 5.50 | — | — | — | — | — | — |
| P/B Ratio | 3.00 | 2.63 | 0.80 | 1.50 | 10.02 | — | — | — | — | — | — |
| P/FCF | 4.56 | 4.53 | 7.75 | — | 33.53 | — | — | — | — | — | — |
| P/OCF | 4.51 | 4.48 | 6.98 | 94.73 | 23.84 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.46 | 0.95 | 1.51 | 6.56 | — | — | — | — | — | — |
| EV / EBITDA | 4.34 | 4.32 | 3.06 | — | — | — | — | — | — | — | — |
| EV / EBIT | 4.66 | 4.79 | 3.53 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 5.20 | 21.98 | — | 40.01 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.8% | 50.8% | 40.9% | 14.0% | 7.0% | 54.1% | 57.5% | 100.0% | 31.8% | -952.0% | — |
| Operating Margin | 31.5% | 31.5% | 27.2% | -12.8% | -185.4% | 51.4% | 55.9% | 35.8% | -2003.4% | -10611.8% | — |
| Net Profit Margin | 8.1% | 8.1% | 10.9% | -18.5% | -193.7% | 40.0% | 38.7% | 21.6% | -3080.0% | 1085.0% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.6% | 22.6% | 37.1% | -45.9% | -272.4% | 78.2% | 106.9% | 84.8% | -645.7% | 24.6% | — |
| ROA | 9.0% | 9.0% | 9.9% | -11.0% | -102.8% | 37.7% | 43.4% | 23.3% | -149.0% | 30.3% | -182.4% |
| ROIC | 38.0% | 38.0% | 23.6% | -6.9% | -88.7% | 42.1% | 52.8% | 32.0% | -109.4% | -155.5% | — |
| ROCE | 43.2% | 43.2% | 30.6% | -8.9% | -110.8% | 53.7% | 79.7% | 65.2% | -206.3% | -240.3% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.83 | 0.83 | 1.69 | 3.49 | 2.22 | 0.93 | 1.02 | 2.36 | — | 0.16 | — |
| Debt / EBITDA | 1.19 | 1.19 | 2.27 | — | — | 1.00 | 0.94 | 3.23 | — | — | — |
| Net Debt / Equity | — | 0.39 | 1.47 | 3.21 | 1.94 | 0.74 | 0.85 | 2.20 | — | 0.16 | — |
| Net Debt / EBITDA | 0.56 | 0.56 | 1.98 | — | — | 0.80 | 0.78 | 3.01 | — | — | — |
| Debt / FCF | — | 0.68 | 14.23 | — | 6.48 | 1.04 | 4.89 | — | — | — | — |
| Interest Coverage | 12.01 | 12.01 | 6.51 | -1.97 | -32.60 | 28.35 | 23.66 | 10.09 | -1.31 | -15.35 | -173.90 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.41 | 3.41 | 2.08 | 1.56 | 1.79 | 4.09 | 4.31 | 0.63 | 0.29 | 0.06 | 0.08 |
| Quick Ratio | 3.39 | 3.39 | 2.06 | 1.50 | 1.72 | 4.01 | 4.25 | 0.62 | 0.27 | 0.06 | 0.08 |
| Cash Ratio | 1.18 | 1.18 | 0.31 | 0.38 | 0.62 | 0.96 | 0.81 | 0.11 | 0.11 | 0.01 | 0.00 |
| Asset Turnover | — | 0.95 | 0.73 | 0.62 | 0.51 | 0.84 | 0.89 | 0.54 | 0.20 | 0.02 | — |
| Inventory Turnover | 150.38 | 150.38 | 99.55 | 62.78 | 57.70 | 54.10 | 67.46 | — | 2.30 | — | — |
| Days Sales Outstanding | — | 135.71 | 179.52 | 92.52 | 97.06 | 126.34 | 144.04 | 135.91 | 743.60 | 42.55 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 4.0% | 4.4% | 4.2% | — | — | — | — | — | — |
| Payout Ratio | — | — | 12.3% | — | — | 108.9% | 55.7% | 90.3% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.6% | 6.4% | 30.6% | — | — | — | — | — | — | — | — |
| FCF Yield | 22.0% | 22.1% | 12.9% | — | 3.0% | — | — | — | — | — | — |
| Buyback Yield | 0.4% | 0.4% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Total Shareholder Yield | 0.4% | 0.4% | 4.0% | 4.4% | 4.2% | — | — | — | — | — | — |
| Shares Outstanding | — | $7M | $5M | $4M | $4M | $4M | $4M | $4M | $7M | $4M | $2M |
Regulatory reimbursement volatility
Based on current market data, Nutex Health trades at a P/S ratio of 1.13 and a P/FCF of 4.03, suggesting that investors are heavily discounting the company's future earnings potential despite the reported 82.36% YoY revenue growth observed in recent financial disclosures.
The absence of a meaningful P/E ratio and the wide disparity between current and forward EV/EBITDA multiples indicate that the market remains uncertain regarding the sustainability of the company's current profitability. This valuation profile suggests that investors are pricing in significant execution risk related to the integration of the PHM division and the potential for future margin compression.
As reported in financial statements, Nutex Health's ROIC has exhibited extreme volatility, ranging from a negative 5.3% in 2023Q4 to a peak of 20.5% in 2024Q4, which highlights the difficulty the firm faces in consistently compounding capital within its micro-hospital and population health management segments.
The erratic nature of these returns suggests that the company's capital allocation strategy is currently struggling to generate stable value, likely due to the high fixed-cost nature of its facilities. Investors should monitor whether the recent stabilization in ROIC near 9.8% in 2026Q1 represents a sustainable trend or merely a temporary byproduct of accounting adjustments.
According to recent SEC filings, the company's cash conversion cycle has fluctuated significantly, reaching a high of 176 days in 2025Q4, which indicates substantial friction in the firm's ability to efficiently convert its service delivery into realized cash collections across its decentralized facility network.
The wide variance in Days Sales Outstanding, which peaked at 216 days in 2025Q4, suggests that the company faces persistent challenges in managing its accounts receivable and payer reimbursement timelines. This inefficiency likely contributes to the observed volatility in free cash flow and warrants further investigation into the underlying quality of the company's revenue streams.
Based on reported figures, Nutex Health has successfully reduced its debt-to-equity ratio to 0.60 as of 2026Q1, providing a robust balance sheet buffer that contrasts sharply with the high-growth, capital-intensive nature of its emergency-grade micro-hospital operations and population health management technology investments.
The company's ability to maintain an interest coverage ratio of 17.36 in the most recent quarter suggests that debt service is currently well-managed, despite the inherent volatility of the business model. This financial positioning provides the firm with significant flexibility to navigate potential regulatory shocks or future capital requirements without immediate reliance on external financing.
Investors frequently misapply traditional hospital P/E and EV/EBITDA multiples to Nutex Health, which obscures the unique value of its cloud-based PHM technology and the high-acuity, decentralized nature of its micro-hospital footprint that differentiates it from large-scale, centralized healthcare providers like HCA Healthcare.
Using standard hospital valuation metrics fails to account for the hybrid nature of the business, where the PHM division is intended to provide recurring, value-based care revenue. A more appropriate approach would involve a sum-of-the-parts analysis that separates the transactional hospital revenue from the potentially higher-multiple, recurring revenue generated by the population health management platform.
Includes 30+ ratios · 13 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NUTX stock.
Nutex Health, Inc.'s current P/E ratio is 17.9x. The historical average is 9.5x. This places it at the 100th percentile of its historical range.
Nutex Health, Inc.'s current EV/EBITDA is 4.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 3.7x.
Nutex Health, Inc.'s return on equity (ROE) is 22.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 2.5%.
Based on historical data, Nutex Health, Inc. is trading at a P/E of 17.9x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nutex Health, Inc. has 50.8% gross margin and 31.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Nutex Health, Inc.'s Debt/EBITDA ratio is 1.2x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.